期刊文献+

胰腺癌患者血清十二种肿瘤标记物的变化 被引量:11

The changes of twelve tumor markers levels in sera of patients with pancreatic cancer
下载PDF
导出
摘要 目的 探讨定量测定胰腺癌患者血清12种肿瘤标志物的临床意义。方法 用蛋白芯片技术定量测定42例正常人、30例胰腺癌和16例胰腺炎患者血清12种肿瘤标志物的变化并对检测效果进行评价。结果 42例正常人血清CA19-9(KU/L)、NSE(μg/L)、CEA(μg/L)、CA242(KU/L)、Ferritin(μg/L)、β-HCG(μg/L)、AFP(μg/L)、f-PSA(μg/L)、PSA(μg/L)、CA125(KU/L)、HGH(μg/L)和CA153(KU/L)的含量分别为:12.42±10.62、2.24±1.41、1.78±1.04、5.73±5.67、91.17±78.47、0.64±0.33、2.96±3.89、0.13±0.11、0.62±1.38、5.46±9.53、1.63±2.37、9.83±9.40;30例胰腺癌患者血清12种肿瘤标志物含量依次为:279.47±402.0、9.50±11.30、8.57±21.95、98.23±89.33、301.98±216.63、1.49±2.28、5.50±7.69、0.27±0.62、1,62±3.23、167.16±252.49、3.38±8.38、43.22±99.34;16例胰腺炎患者其含量依次为:53.38±86.38、12.78±28.50、1.20±0.94、22.99±51.13、343.43±308.27、3.63±11.99、5.09±3.66、0.10±1.32、0.66±0.61、98.67±212.23、1.79±1.63、4.15±2.13。该蛋白芯片测定的敏感性为70.0%,特异性为89.7%,阳性预测值为77.8%,阴性预测值为88.1%。结论 采用蛋白芯片技术同时测定患者血清中多种肿? Objective To study the clinical significance of serum 12 tumor markers levels in patients with pancreatic cancer. Methods The values of serum 12 tumor markers were detected by a proteinchip in 42 controls, 30 pancreatic cancers and 16 pancreatitis. The clinical effect of using the proteinchip was evaluated. Results Serum levels of CA19-9(KU/L), NSE(μg/L), CEA(μg/L), CA242(KU/L), Ferritin (μg/L) , β-HCG (μg/L), AFP(μg/L), f-PSA(μg/L), PSA(μ g/L), CA125 ( KU/L), HGH(g/L)and CA153(KU/L) were 12. 42 ± 10. 62, 2. 24±1. 41, 1. 78 ± 1. 04, 5. 73 ± 5.67, 91.17 ± 78.47, 0.64 ±0.33,2.96±3.89,0.13±0.11,0.62±1.38,5.46±9. 53, 1.63 ± 2.37 and 9. 83 ± 9. 40 in controls, 279. 47 ± 402. 0, 9. 50±11. 30, 8. 57 ± 21. 95, 98. 23 ± 89. 33, 301. 98 ± 216. 63, 1. 49 ± 2. 28, 5. 50 ± 7. 69, 0. 27 ± 0. 62, 1. 62 ± 3. 23, 167. 16 ± 252. 49, 3. 38 ± 8. 38 and 43. 22±99. 34 in 30 pancreatic cancer, 53. 38 ± 86. 38, 12. 78 ± 28. 50, 1. 20 ± 0. 94, 22. 99 ± 51. 13, 343.43 ± 308.27, 3.63 ± 11.99, 5.09 ± 3.66, 0.10 ± 1.32, 0.66 ± 0.61, 98.67 ± 212.23, 1.79 ± 1.63 and 4. 15 ± 2. 13 in 16 pancreatitis, respectively. The sensitivity and specificity, positive and negative predictive values of the proteinchip determination were 70. 0%, 89. 7%, 77. 8% and 88. 1%, respectively. Conclusions Multi-tumor markers levels in serum can be detected by using proteinchip. The proteinchip was proved to be useful in survey and observation of curative effect for patients with carcinoma.
出处 《胰腺病学》 2002年第3期151-154,共4页 Chinese JOurnal of Pancreatology
关键词 胰腺癌 血清 肿瘤标记物 蛋白芯片 测定 Tumor markers Proteinchip Pancreatic cancer
  • 相关文献

参考文献6

  • 1Banfi G, Bravi S, Ardemagni A, et al.CA19-9,CA242 and CEA in the diagnosis and follow-up of pancreatic cancer.Int J Biol Markers,1996,2:77-81.
  • 2Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer, 1996, 3:372-376.
  • 3Nishida K, Kaneko T, Yoneda M, et al. Doubling time of serum CA19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.J Surg Oncol, 1999, 3:140-146.
  • 4Kim H J,Kim M H,Myung S J,et al.A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer:analysis using a receiver operating characteristic curve.Am J Gastroenterol, 1999, 7:1941-1946.
  • 5王平,李玉明.血清CA19-9、CA24-2、CEA联合检测在胰癌诊断中的价值[J].南通医学院学报,1997,17(4):488-489. 被引量:6
  • 6张乐之,龚燕芳,屠振兴.胰腺癌患者血清CA242定量测定及其意义[J].胰腺病学,2002,2(1):20-21. 被引量:28

二级参考文献4

  • 1Haglund C,Lundin J,Kuusela P,et al. CA242,a new tumout ma rker for pancreatic cancer:a comparison with CA19-9,CAS0 and CEA. Br J Cancer, 1994,70: 487-492
  • 2Pasanen PA,Eskelinen M, Partanen K,et al. Clinical evaluation of a new serum tumour marker CA242 in pancreatic carcinoma. Br J Cancer, 1992,65: 731-734
  • 3Rothlin MA,Joller H,Largiader F. CA242 is a new tumour mar ker for pancreatic cancer. Cancer, 1993,71: 701-707
  • 4徐有青,王丽华,刘慧丰,田自然.肿瘤标志物CA242与CA19-9对胰腺癌的诊断作用研究[J].中国肿瘤临床,1999,26(2):113-114. 被引量:14

共引文献31

同被引文献70

引证文献11

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部